NGNE – neurogene inc. (US:NASDAQ)
Stock Stats
News
Neurogene Inc. (NASDAQ: NGNE) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $65.00 price target on the stock.
Neurogene Inc. (NASDAQ: NGNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
Meridian Small Cap Growth Fund Trimmed Neurogene (NGNE) on Share Price Appreciation [Yahoo! Finance]
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome [Yahoo! Finance]
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Form 8-K Neurogene Inc. For: Jun 21
Form 8-K Neurogene Inc. For: Jun 18
Form 4 Neurogene Inc. For: Jun 14 Filed by: Woods Robert Keith
Form 4 Neurogene Inc. For: Jun 14 Filed by: PALEKAR ROHAN
Form 4 Neurogene Inc. For: Jun 14 Filed by: BAFFI ROBERT
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.